Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development.
about
Mitochondrial targets for pharmacological intervention in human diseaseThe pathobiology of acute coronary syndromes: clinical implications and central role of the mitochondriaTargeting mitochondrial cardiolipin and the cytochrome c/cardiolipin complex to promote electron transport and optimize mitochondrial ATP synthesisFirst-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergeticsSerendipity and the discovery of novel compounds that restore mitochondrial plasticityMitochondrial dysfunction in cardiac agingReduction of early reperfusion injury with the mitochondria-targeting peptide bendaviaMitochondria-targeting particles.Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications.Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubesSphingomyelinase depresses force and calcium sensitivity of the contractile apparatus in mouse diaphragm muscle fibers.Molecular basis of intramolecular electron transfer in proteins during radical-mediated oxidations: computer simulation studies in model tyrosine-cysteine peptides in solution.Pharmacological targeting of mitochondrial reactive oxygen species counteracts diaphragm weakness in chronic heart failure.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbersBiological relevance of inflammation and oxidative stress in the pathogenesis of arterial diseases.TNF signals via neuronal-type nitric oxide synthase and reactive oxygen species to depress specific force of skeletal muscle.Peroxynitrite, a stealthy biological oxidant.Kinetic and mechanistic considerations to assess the biological fate of peroxynitrite.Expert consensus document: Mitochondrial function as a therapeutic target in heart failureManganese superoxide dismutase, MnSOD and its mimicsThe bad, the good, and the ugly about oxidative stress.Targeting malignant mitochondria with therapeutic peptides.Perspectives and potential applications of mitochondria-targeted antioxidants in cardiometabolic diseases and type 2 diabetes.Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention.Mitochondrial potassium channels as pharmacological target for cardioprotective drugs.Using chemical biology to assess and modulate mitochondria: progress and challenges.Mitochondrial Therapies in Heart Failure.A Powerful Mitochondria-Targeted Iron Chelator Affords High Photoprotection against Solar Ultraviolet A Radiation.Mitochondria in Acute Kidney Injury.Gold nanoparticle-enhanced photodynamic therapy: effects of surface charge and mitochondrial targeting.Nutritional interventions in primary mitochondrial disorders: Developing an evidence base.A Mitocentric View of Alzheimer's Disease.Eating the Dead to Keep Atherosclerosis at Bay.Mitochondria-Targeted Triphenylphosphonium-Based Compounds: Syntheses, Mechanisms of Action, and Therapeutic and Diagnostic Applications.Solution-phase-peptide synthesis via the group-assisted purification (GAP) chemistry without using chromatography and recrystallization.Mitochondrial hepatopathies: advances in genetics, therapeutic approaches, and outcomes.Maintaining mitochondrial morphology in AKI: looks matter.New and revisited approaches to preserving the reperfused myocardium.Mitochondrion-Targeted Peptide SS-31 Inhibited Oxidized Low-Density Lipoproteins-Induced Foam Cell Formation through both ROS Scavenging and Inhibition of Cholesterol Influx in RAW264.7 Cells.Antioxidant treatments do not improve force recovery after fatiguing stimulation of mouse skeletal muscle fibres.
P2860
Q26824514-D53A0AD4-A77D-4170-97E9-1520DB58BCFCQ27026299-99708263-3F52-45EB-A07F-1638B79B919EQ28383442-AA056AB2-F29E-419F-A25C-B4D63A3E27BBQ28383451-5AC23B1B-FD01-4E6E-88B1-39CC245F1316Q28384256-A2CB8EF4-76D2-4C93-9C58-565FC7BE03B5Q28389063-2E2E0E8A-E0B9-4980-87D1-DAFB780F01FDQ33919143-30C4B2B5-F81F-460E-9056-900C6FA1DB3AQ34960940-4CCB4CF4-A5A0-4A26-875F-F7A4D59D1F4DQ35148462-21A43301-CB84-4317-BC9D-7065C5A20CD7Q35895750-256F90A6-D763-4474-A5C4-6816A5C9D31AQ35994710-C1589CF5-0D34-4E5A-964D-2988F860AA1CQ36148604-C8062203-C610-4915-9516-6D57249AF948Q36775314-B197561B-8CF4-4D68-BDAB-D417504C0C7AQ36799584-A84E4E3A-9BAC-4C28-8BA7-CDBEF40B3704Q36817578-13388EF4-29CC-4197-BC04-C4675053BFD2Q36924162-328B8FFA-E855-477A-A59E-EA28C44B96EBQ37168344-F4C131CA-B251-4FB4-8A07-866D09FD1062Q37381268-E7247B6D-D1ED-4070-B3BB-EB32F48587F7Q37699474-49604DA5-80D6-45A2-AAEC-93C2F42C6BC2Q37971277-2239DF56-5311-429D-AA59-EB93B35863C7Q38012450-68CAFEC7-2B48-4B8C-AA33-076733D0921CQ38040407-3C0C5AED-40A7-408A-BDE2-6484B4A570D5Q38104693-8794194E-4470-411D-B60D-74AB7C4742D5Q38222708-241B2AA6-0776-470B-AF2F-7306BD9A4984Q38262884-E37BF192-D4FA-47B0-BFDD-7EAB9AB04AD8Q38734360-24D9A3DA-81D7-44CA-A16A-ECAD9A59D53CQ38759545-93BB0C9D-DA4F-482F-A4B5-B1DF65AFF0C7Q38775707-96162461-9995-4053-A3F3-C56BE5E2B1FEQ38809996-0239F68F-F682-4D93-8A4B-D02BFE7D228FQ38889799-8894C211-568A-439D-861A-2C2F79D854ADQ38963725-1801B69E-0291-4DD8-866B-1C88D8E6EFBBQ38970508-F11E5066-595A-4612-B2A0-D172C7B1533EQ39134393-6F5CAAA1-118E-45D2-BA8C-FF4B1BFDC0A1Q39400621-926A046C-25FC-4ED0-9E3F-8365E47FDC21Q41965730-A471B99A-ADBE-4E5B-8262-58E86F59A785Q41977878-C94E27D4-5A9E-4D7A-A802-C5F3B4489212Q42543463-C207F3F9-F85E-4C8E-8B5A-766FA0A4B2EEQ45064238-39D0EB2D-5C6E-4449-962C-78C3722AEEBFQ46628733-5C83B1A6-B843-486D-8995-DE0FA5FFC35AQ46780893-2BB3841B-DFD2-4EF8-9C63-26A70CA139DE
P2860
Novel therapies targeting inner mitochondrial membrane--from discovery to clinical development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Novel therapies targeting inne ...... overy to clinical development.
@en
Novel therapies targeting inne ...... overy to clinical development.
@nl
type
label
Novel therapies targeting inne ...... overy to clinical development.
@en
Novel therapies targeting inne ...... overy to clinical development.
@nl
prefLabel
Novel therapies targeting inne ...... overy to clinical development.
@en
Novel therapies targeting inne ...... overy to clinical development.
@nl
P2860
P1476
Novel therapies targeting inne ...... overy to clinical development.
@en
P2093
Hazel H Szeto
Peter W Schiller
P2860
P304
P356
10.1007/S11095-011-0476-8
P577
2011-06-03T00:00:00Z